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http://dx.doi.org/10.10nitive disorders (MCD) in cohorts in their 60s, at an age when diagnoses are less stable. The authors’
goal was to estimate the incidence and prevalence of MCI and MCD, characterize subgroups with
stable vs nonstable diagnoses, and evaluate the impact of diagnosis on daily life in a young-old cohort.
Methods: A community-based cohort age 60 to 64 years in 1999 (n 5 2551) was monitored for 8
years and assessed every 4 years. A two-stage sampling design was used to identify MCI and
MCD through a neuropsychological and neurological assessment. A panel of physicians blind to
previous diagnoses reviewed each case using published criteria.
Results: The prevalence of MCDs in the cohort aged 68 to 72 years at the last follow-up was approx-
imately 10%. An estimated 141 subjects (7.7%) progressed to MCI and 183 subjects (10.0%) pro-
gressed to MCD between years 4 and 8. Only eight participants received a dementia diagnosis at
any wave, five of whom progressed from MCDs. More than 45% of diagnoses were unstable during
the 8 years of follow-up. Stable diagnoses were associated with lower Mini-Mental State Examina-
tion scores, history of neurological disorder, higher cardiovascular risk, and depression at baseline.
MCDs were associated with impairments in instrumental activities of daily living and higher rates
of reporting memory problems prior to diagnosis.
Conclusions: MCDs in individuals in their 60s occur in at least 10% of the population and are likely
to be heterogeneous in terms of their etiology and long-term prognosis, but may cause a significant
impact in everyday life.
 2013 The Alzheimer’s Association. Open access under CC BY-NC-ND license.Keywords: MCI; Incidence study; Cohort study; Dementiaanmalee Eramudugolla, and Dr Kerry Sargent-Cox
al analysis.
study concept, design, analysis, interpretation, draft-
ervision of study. Dr Cherbuin participated in study
ision of the manuscript for important intellectual con-
nd Dr Eramudugolla participated in analysis and crit-
manuscript for important intellectual content. Prof
n study concept and design. Dr Kumar participated
critical revision of the manuscript for important in-
f Sachdev participated in study concept, study design,
f the manuscript for important intellectual content.
thor. Tel.: 1612 61253858; Fax: 1612 61250733.
arin.anstey@anu.edu.au
he Alzheimer’s Association.
16/j.jalz.2012.11.013
Open access under CC BY-NC1. Introduction
Most of the research on mild cognitive impairment
(MCI) and related definitions of preclinical dementia
syndromes has been conducted in adults age 70 years
or older [1]. There are few studies available from which
to ascertain the incidence, prevalence, and course of MCI
in individuals in their 60s, the stability of diagnoses at
this age, and the impact cognitive impairment has on em-
ployment and everyday life. Characterizing MCI clini-
cally in its earliest stages is required to provide
a complete picture of the epidemiology of neurocognitive-ND license.
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in guiding treatment decisions.
Conversion rates of MCI to Alzheimer’s disease (AD)
and other dementias are highly age dependent and variable
[2]. Unless patients who ultimately develop dementia are
assessed prior to diagnosis of a mild cognitive disorder
(MCD), the true duration of the MCI stage at the popula-
tion level is not estimable. Our aim is to characterize cog-
nitive impairment at an age when many older adults
remain in the workforce and are actively engaged in their
community. Following results from our previous two
waves [3,4], we estimate the incidence of MCI [5] and
a broader category of MCD [3] in a young-old cohort in
their 60s and evaluate factors associated with the stability
of diagnoses in this age range. We also evaluate the asso-
ciation between MCDs and perceived memory difficulties,
reports of attending a general practitioner for memory dif-
ficulties, and problems with instrumental activities of daily
living (IADLs).2. Methods
2.1. Study participants
Participants were sampled randomly from the electoral
rolls for Canberra, ACT, and Queanbeyan, NSW, Australia,
as part of the Personality and Total Health (PATH) Through
Life Project [6]. They were asked to complete a question-
naire under the supervision of a professional interviewer.
Cognitive and physical tests were also carried out and
a cheek swab was taken from which DNA could be ex-
tracted. Written informed consent was obtained from all par-
ticipants prior to involvement in the study, and the Australian
National University Human Research Ethics Committee ap-
proved the study. The oldest cohort is the focus of this study
and was 60 to 64 years at wave 1; interviews were conducted
in 2001 to 2002 (n 5 2551), 2005 to 2006 (n 5 2222), and
2009 to 2010 (n 5 1973). The design of the PATH Through
Life Project and the methodology for clinical diagnoses have
been described elsewhere [3,4,6].
2.2. Screening
At each wave, the same predetermined cutoff on a cogni-
tive screening battery was used to screen participants into
a substudy on MCDs and dementia. Participants from the
full cohort were selected for clinical assessment if they
had any of the following: (i) a Mini-Mental State Examina-
tion (MMSE) [7] score  25, (ii) a score below the fifth
percentile score from wave 1 on immediate or delayed recall
of the California Verbal Learning Test [8] (immediate or
delayed score of ,4 and ,2, respectively), or (iii) a score
below the fifth percentile on two or more of the following
tests: Symbol-Digit Modalities Test [9] (,33) or Purdue
Pegboard with both hands [10] (wave 1, ,8; wave 2, ,7),
or simple reaction time [11] (third set of 20 trials; wave 1,
.310 ms; wave 2, .378 ms).2.3. Clinical assessment
The clinical assessment involved a Structured Clinical As-
sessment for Dementia (available from us) by one of two phy-
sicians, a neuropsychological assessment, and the Clinical
Dementia Rating Scale [12]. Information was also gathered
on medical history related to cognitive function, duration of
symptoms, medical history from medical practitioners and
family, current treatment, and psychiatric history. Depression
was assessed using the self-administered Patient Health
Questionnaire from thePrimaryCareEvaluationofMentalDis-
orders (PRIME-MD) [13]. Informant interviews were conduct-
ed when possible. Participants receiving any clinical diagnosis
were referred to their family doctor for laboratory investiga-
tions. The research protocol included magnetic resonance im-
aging for all consenting participants. The neuropsychological
assessment included frontal executive function (Trails A and
B[14],VerbalFluency [15], andClockDrawing [16]), language
(Boston Naming Short Form [17]), constructional praxis from
theConsortium to Establish a Registry for Alzheimer’s Disease
battery [18], memory (ReyAuditory Verbal Learning Test with
verbal recall and recognition [19]) recall of constructional
praxis for nonverbal memory, and agnosia [20].
Clinicians used clinical checklists, data from the neuro-
psychological assessment, neuropsychiatric history, and
medical history to formulate consensus diagnoses. Criteria
for the following diagnoses were applied: MCI [5,21],
age-associated memory impairment [22], age-associated
cognitive decline [23], mild neurocognitive disorder [24],
impairment on the Clinical Dementia Rating Scale [12],
and other cognitive disorder [24]. Diagnostic and Statistical
Manual of Mental Disorders, 4th edition, criteria were used
to assess dementia and delirium [24]. The Petersen criteria
for MCI were used at waves 1 and 2 [21], whereas the Win-
blad criteria [5] were used at wave 3. For all other categories,
the same criteria were used for all three waves and have been
published by our group elsewhere [4]. A description of crite-
ria is included in the online supplementary material. Impor-
tant for this study, clinicians were blind to the presence or
lack of diagnosis obtained at waves 1 and 2.2.3.1. Assessment of self-reported impact of memory on
function
Atwaves 1 and 2 participants were asked: Do you feel you
can remember things as well as you used to? That is, is your
memory the same as itwas earlier in life? If they answered no,
then theywere asked: Does this memory problem interfere in
anyway with your day-to-day life? And have you seen a doc-
tor about your memory? IADLs were assessed at wave 3 with
items adapted from the U.S. Health and Retirement Study
[25] and included difficulty reading a map, preparing meals,
shopping for groceries, and making telephone calls.2.3.2. Health measures
During the interview, data were collected on history of
neurological disorders and thyroid conditions. Information
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and diabetes mellitus and its treatment were obtained via
self-report, and blood pressure was measured. These vari-
ableswere combinedwith age and sex to compute a Framing-
ham cardiovascular risk score for each participant [26].Table 1
Wave 3 prevalence of mild cognitive disorder
Diagnostic category Prevalence wave 3, % 95% CI
MCD 9.97 (4.31–15.63)
MCI 7.68 (3.50–13.33)
MND 4.06 (0.83–7.91)
AACD 5.63 (1.82–10.26)
CDR  0.5 7.91 (3.09–12.73)
Abbreviations: CI, confidence interval; MCD, mild cognitive disorder;
MCI, mild cognitive impairment; MND, mild neurocognitive disorder;
AACD, age-associated cognitive decline; CDR, Clinical Dementia Rating.
NOTE. A reliable prevalence estimate of age-associated memory impair-
ment (AAMI) and other cognitive disorder (OCD) according to the Diag-
nostic and Statistical Manual of Mental Disorders, 4th edition, could not
be calculated. MCD comprises any person meeting criteria for MCI,
MND, AACD, AAMI, CDR  0.5, or OCD.3. Data analysis
Group comparisons were made with analysis of variance
for continuous variables or c2 tests for frequencies. To iden-
tify factors associated with diagnostic instability, we evalu-
ated whether a range of factors previously associated with
cognitive fluctuation and cognitive decline in the literature
differed among groups. These included both depression at
baseline and variability in depression over time [27], base-
line anticholinergic medication and variability in anticholin-
ergic burden [28,29], history of thyroid disorder [30,31],
history of neurological disorder, and baseline cardio-
vascular risk profile [32,33].
To establish predicted prevalence and incidence rates for
the cohort, predictive regression models were built based on
the relationship between the screening measures and the
clinical data for the subsample for which diagnostic data
were available using methods described previously [3]. It
was necessary to compute prevalence among participants
who screened positive but who did not undertake the clinical
assessment, and to estimate the false negatives in the sample
that screened negative. Using the clinical diagnoses as the
gold standard, logistic regressions with age, sex, and screen-
ing measures as predictor variables were built. For each di-
agnostic criterion, a predictive score defined as the
probability of positive diagnosis was derived and a cutoff
point was chosen so that the number of predicted diagnoses
was the same as the number of observed diagnoses under the
criterion in the subsample. This cutoff point was then ap-
plied to the predictive score of those who screened positive
but did not undertake the clinical assessment and those
who screened negative. The final prevalence estimate was
a sum of those receiving clinical diagnoses, those estimated
to receive a diagnosis among the group that screened positive
but did not receive a diagnosis, and those estimated to have
been falsely screened as negative. To estimate the influence
of attrition on the overall incidence rates data were imputed
(using the expectation maximization algorithm) for 269 par-
ticipants not monitored up from wave 2 to wave 3. Imputa-
tion was estimated using wave 1 and wave 2 cognition
data, gender, and age.
The impact of attrition on estimates was evaluated by ap-
plying the predictive regression equations to the subgroups’
most recent cognitive assessment data (wave 2) to estimate
conservatively the proportion lost to follow-up with likely
cognitive impairment.
Confidence intervals and standard errors for the preva-
lence estimate were estimated using bootstrap techniques.
The logistic regression linking the diagnostic data and the
screening data was fitted to 1000 bootstrap samples, andthe population prevalence estimate was then calculated as
the average of prevalence estimates across bootstrap sam-
ples. The 95% confidence interval was calculated by taking
the 2.5th and 97.5th percentile of the bootstrap prevalence
estimates. Analyses were conducted in IBM SPSS19
(Armok, NY, USA) and STATA version 9.0 (College
Station, TX, USA).4. Results
4.1. Sample size and demographics
At wave 3, the sample had a mean age of 70.60 years
(standard deviation [SD], 1.50 years; range, 68–72 years),
including 1020 males (51.7%). The sample had a mean of
13.98 years (SD, 2.7 years) of education.4.2. Prevalence and incidence rates derived from
statistical modeling
Incidence rates were estimated from the 2047 participants
who were free from clinical diagnosis at wave 2. Of these in-
dividuals, 1838 were available for assessment at wave 3. Us-
ing the statistical estimates based on the screening measures
applied to the entire sample, an estimated 141 (7.7%) partic-
ipants converted to MCI and 183 (10.0%) converted to MCD
during 4 years, indicating an incidence rate of 19.18 cases of
MCI/1000 person-years and 24.89 cases of MCD/1000
person-years. Rates for conversion to MCI and MCD were
higher for males (MCI, 9.3%; MCD, 11.7%) than females
(MCI, 5.9%; MCD, 8.2%; P, .01). Of participants with sta-
tistically derived diagnoses who screened negative and
therefore did not undergo a clinical assessment, 73 received
a diagnosis ofMCI and 95 received a diagnosis ofMCD. The
statistically estimated prevalence rates of MCDs in the co-
hort at wave 3 (not including imputed data from those lost
at wave 2) are shown in Table 1.
In the subsample lost to attrition (n 5 269), it was esti-
mated that 33 (12.3%) progressed to MCI and 28 (10.4%)
to MCD. Combining these predicted conversions with the
full wave 3 sample, the incidence rate was calculated to
Table 2
Classification of MCI/MCD participants across three waves of the study
Diagnosis
Classification at each wave Total, n (%)*
Wave 1 Wave 2 Wave 3 MCD MCI
Unstable 76 (51) 40 (45.5)
Normal MCD/MCI Normal 35 (23.5) 15 (17.0)
MCD/MCI Normal Normal 17 (11.4) 16 (18.2)
MCD/MCI Normal MCD/MCI 4 (2.7) 3 (3.4)
MCD/MCI MCD/MCI Normal 20 (13.4) 6 (6.8)
Stable
diagnosisy
42 (28.2) 15 (17.0)
MCD/MCI MCD/MCI MCD/MCI 17 (11.4) 2 (2.3)
Normal MCD/MCI MCD/MCI 25 (16.8) 13 (14.8)
New diagnosis 31 (20.8) 33 (37.5)
Normal Normal MCD/MCI 30 (20.7) 33 (37.5)
Normal Missing MCD/MCI 1 (0.7)
Abbreviations: MCD, mild cognitive disorder; MCI, mild cognitive im-
pairment.
NOTE. Totals for diagnosis groups marked in bold.
*Percentages based on prevalent cases during the 8-year study period
(MCD: n 5 149; MCI: n 5 93).
yStability of classification is defined as consecutive diagnoses across mul-
tiple assessments [34] without reversion to normalcy [35,36].
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of 1.47 cases) and 25.04 cases/1000 person-years for MCD
(an increase of 0.15 cases).
4.2.1. Classification of stable and unstable MCD and MCI
All participants with an MCI/MCD diagnosis at any point
in the study (MCI, n5 149; MCD, n5 93) were classified as
stable, unstable, or new cases (Table 2 [34–36]). Participants
with a first diagnosis of any MCD/MCI at wave 3 were
classified as new cases (any MCD, n 5 31; MCI, n 5 33).
Of the participants with previous diagnoses of any MCD/
MCI, stable cases were defined as those with consecutiveTable 3
Demographic and baseline clinical characteristics for the cohort at wave 3 (n 5 1
Diagnostic
group n
Age at wave 3,
Years
Gender,
male, n (%)
No. of years of
education
Undiagnosed 1816 70.61 (1.49) 925 (50.9) 14.11 (2.65)
Unstable MCD* 76 70.79 (1.46) 45 (59.2) 12.45 (2.72)x
Stable MCD* 42 69.95 (1.46) 26 (61.9) 12.29 (2.77)x
New MCD cases* 31 70.77 (1.67) 19 (61.3) 13.22 (3.08)
Dementia 8 71.00 (1.51) 5 (62.5) 12.75 (2.90)
c2 or F statisticy 2.54z 5.41 12.49x
Unstable MCI* 40 70.60 (1.52) 25 (62.5) 12.02 (2.81)x
Stable MCI* 15 69.87 (1.41) 10 (66.7) 11.73 (2.68)x
New MCI cases* 33 70.73 (1.57) 20 (60.6) 13.02 (2.99)
c2 or F statisticy 1.11 4.87 9.92x
Abbreviations: NESB, non-English-speaking background; APOE, apolipoprotei
tistical Manual of Mental Disorders, 4th edition; MCD, mild cognitive disorder;
NOTE. The depression score was on the Patient Health Questionnaire Depressi
*Difference across all groups (omnibus test): undiagnosed, stable/unstable/new
yBonferroni adjusted comparisons between MCI/MCD group and undiagnosed
zP , .05
xP , .01
{P , .06diagnoses across multiple assessments [34] without rever-
sion to normalcy [35,36] (any MCD, n 5 42; MCI, n 5
15). The remaining participants were classified unstable
and comprised those with a prior diagnosis who had
reverted to normalcy at wave 3, and those with a current
diagnosis but nonconsecutive prior diagnoses (any MCD,
n 5 76; MCI, n 5 40). Participants who progressed to
dementia were categorized separately (n 5 8).4.3. Characteristics of normal and clinical groups
Baseline demographic and cognitive characteristics of
participants who remained without diagnosis and those diag-
nosed with MCI, any MCD, and dementia are shown in
Table 3. During the entire 8 years of follow-up, 187 partici-
pants received a diagnosis of any MCD (149 of whom were
available at wave 3) and eight participants progressed to de-
mentia. Of the participants diagnosed with an MCD during
the study, approximately half demonstrated diagnostic insta-
bility, reverting to normal cognitive status during wave 3
(Fig. 1). Table 3 presents the demographic and baseline clin-
ical characteristics for all participants available for study at
wave 3. The diagnostic groups differed on the basis of level
of education, proportion of participants from a non-English-
speaking background, baseline levels of employment, de-
pression, and MMSE scores.
Relative to undiagnosed participants, thosewith a diagno-
sis of either stable or unstable MCI/MCD had significantly
lower education, lower baseline MMSE scores, and were
more likely to be of a non-English-speaking background
(6.2% vs 16.0-31.0%). In addition, a stable diagnosis of
MCI/MCD was associated with lower rates of baseline em-
ployment (13.3-16.7% vs 43.3%) and more severe depres-
sion at baseline (3.55 [SD, 4.39] vs 2.25 [SD, 2.92]). The973).
NESB
APOE e4
genotype
Baseline mood and cognitive status
Employed at
wave 1 MMSE score
DSM-IV
depression
111 (6.2) 463 (26.9) 787 (43.3) 29.36 (1.04) 2.25 (2.92)
12 (16.0)x 18 (24.0) 30 (39.5) 28.21 (1.95)x 2.63 (3.32)
13 (31.0)x 7 (16.7) 7 (16.7)x 27.12 (2.92)x 3.55 (4.39){
5 (16.1) 13 (43.3)z 8 (25.8) 28.06 (1.41)z 3.03 (3.68)
1 (12.5) 4 (50.0) 4 (50.0) 28.63 (1.06) 2.38 (3.58)
50.00x 8.83{ 16.06x 63.18x 2.63z
13 (33.3) 9 (22.5) 20 (50.0) 27.50 (2.29)x 2.90 (3.39)
7 (46.7) 2 (13.3) 2 (13.3) 26.76 (3.16)x 4.00 (5.25)
4 (12.1) 10 (31.2) 9 (27.3) 27.84 (1.71)x 2.69 (3.91)
77.68x 4.28 9.14z 58.24x 1.78
n E; MMSE, Mini-Mental State Examination; DSM-IV, Diagnostic and Sta-
MCI, mild cognitive impairment.
on Scale.
MCD/MCI, dementia.
group.
Fig. 1. (A, B) Flow diagram depicting progression of participants with mild cognitive disorders through the PATHThrough Life Project. Participant progression
across waves as a function of mild cognitive impairment (MCI) diagnosis (A) and mild cognitive disorder (MCD) diagnosis (B). *Participants reverting to nor-
mal state in wave 3 categorized as unstable diagnosis.
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(APOE) e4 alleles did not differ significantly across groups,
and was 26.9% in the undiagnosed group, ranged from
13.3% to 43.3% in the MCI/MCD categories, and was
50% for dementia.
At wave 3, clinical interview and neuropsychological
testing of MCI/MCD participants established 26 indi-
viduals as amnestic single-domain MCI, 21 as amnestic
multidomain MCI, and four individuals as nonamnestic
multidomain MCI. None were diagnosed with nonamnestic
single-domain MCI. Of the 51 participants diagnosed with
the wave 3 MCI criteria [5], 47 also met the wave 1 MCI
criteria [21] at wave 3.4.4. Clinical and demographic factors associated with
diagnostic stability over 8 years
Comparisons of stable and unstable MCD and MCI
groups are shown in Table 4. Diagnostic stability for MCD
was associated with lower baseline MMSE scores and
increased frequency of neurological disorders. Diagnostic
stability for MCI was associated with a higher Framingham
cardiovascular 10-year risk profile calculated at baseline and
history of neurological disorder. None of the other potential
explanatory influences on cognitive fluctuation differenti-
ated diagnostic stability. Participants categorized as stable
were also significantly more likely to report memory
Table 4
Factors differentiating the diagnostic stability of MCIs
Variable
MCD
P value
MCI
P valueUnstable Stable New cases Unstable Stable New cases
Years of education 12.45 (2.72) 12.29 (2.77) 13.22 (3.08) NS 12.02 (2.81) 11.73 (2.68) 13.02 (2.99) NS
MMSE score at baseline 28.21 (1.95) 27.12 (2.92)z 28.06 (1.41) ,.05 28.21 (1.95) 27.12 (2.92) 28.06 (1.41) NS
Depression at baseline 2.63 (3.32) 3.55 (4.39) 3.03 (3.68) NS 2.90 (3.39) 4.00 (5.25) 2.69 (3.91) NS
Variability in depression* 1.84 (1.83) 2.38 (2.13) 2.13 (1.83) NS 1.53 (1.43) 1.39 (1.16) 1.27 (1.24) NS
Variability in anticholinergic burden* 0.30 (0.49) 0.37 (0.51) 0.34 (0.48) NS 0.32 (0.49) 0.34 (0.43) 0.34 (0.54) NS
Framingham relative risk at baseline 0.69 (0.29) 0.71 (0.32) 0.73 (0.22) NS 0.61 (0.23) 0.82 (0.40)z 0.71 (0.27) ,.05
Non-English speaking background, n (%) 12 (16.0) 13 (31.0) 5 (16.1) NS 13 (33.3) 7 (46.7) 4 (12.1)z ,.05
APOE e4 carriage, n (%) 18 (24.0) 7 (16.7) 13 (43.3)z ,.05 9 (22.5) 2 (13.3) 10 (31.2) NS
White, n (%) 71 (93.4) 37 (88.1) 30 (96.8) NS 34 (85.0) 12 (80.0) 32 (97.0) NS
History of neurological disorder, n (%)z 17 (22.4) 14 (33.3) 12 (38.7) NS 7 (17.5) 2 (13.3) 13 (39.4)z ,.05
History of thyroid disorder, n (%) 11 (14.5) 8 (19.0) 6 (19.4) NS 5 (12.5) 1 (6.7) 7 (21.2) NS
Anticholinergic medications at baseline, n (%) 13 (17.1) 5 (11.9) 4 (12.9) NS 6 (15.0) 1 (6.7) 3 (9.1) NS
Subjective memory complaints, yes, n (%) 17 (22.4) 14 (33.3) 7 (22.6) NS 8 (20.0) 3 (20.0) 10 (30.3) NS
Abbreviations: MCD, mild cognitive disorder; MCI, mild cognitive impairment; NS, not significant; MMSE, Mini-Mental State Examination; APOE, apo-
lipoprotein E.
* Mean absolute deviation of individuals’ scores across waves.
y Any history of stroke, epilepsy, head injury, brain tumor, brain infection, or parkinsonism.
zP , .05 for pairwise comparison relative to unstable MCD/MCI group.
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diagnosis.
4.5. Impact of cognitive impairment on memory
complaints and IADLs
Impact of cognitive impairment was evaluated by exam-
ining medical consultations related to memory, memory
complaints, and problems with IADLs (Table 5). The stable
MCD group had higher rates of reporting they had consulted
a doctor about their memory in wave 2, and higher rates of
reporting memory interfering with their daily activities inTable 5
Self-reported memory and impact on IADLs by diagnostic stability of MCD and
Undiagnosed
MCD
Unstable Stable New diagnoses
Reporting yes, % Reporting yes, %
Memory worse than used to be
Wave 1 24.1 26.3 14.3 19.4
Wave 2 18.4 13.2 16.7 13.3
Memory interferes with daily life
Wave 1 8.8 14.3 27.8* 28*
Wave 2 9.6 16.7 28.6* 34.6*
Consulted doctor about memory
Wave 1 2.3 23.1 16.7 37.5
Wave 2 2.3 21.4 53.8* 40
IADLs, wave 3 Reporting yes, n (%) Reporting yes, n (%)
Any IADL problems 254 (14.0) 11 (14.5) 14 (33.3)*
Problems in map reading 149 (8.2) 7 (9.2) 7 (16.2)
Problems preparing meals 36 (2.0) 3 (3.9) 3 (7.1)
Problems grocery shopping 64 (3.5) 1 (1.3) 3 (1.5)
Problems making phone calls 25 (1.4) 2 (2.6) 2 (4.8)
Problems taking medications 21 (1.2) 1 (1.3) 3 (7.1)*
Abbreviations: MCD, mild cognitive disorder; MCI, mild cognitive impairmen
*P , .05, pairwise comparisons with undiagnosed group.both waves 1 and 2, relative to the undiagnosed group as
well as to the unstable MCD group.
Participants with a stable MCI or MCD diagnosis at wave 3
reportedmore difficulties readingmaps, shopping,making tele-
phone calls, and taking medications. All groups reported low
levels of problemswithmeal preparation and grocery shopping.5. Discussion
The current study adds to the two previous reports of MCI
and any MCD in this sample [3,4] to provide resultsMCI
P value
MCI
P value
Unstable Stable New diagnoses
Reporting yes, %
NS 10 13.3 21.2 NS
NS 5 20 21.9 NS
,.01 17.5 33.3* 21.2* ,.001
,.001 20* 26.7* 24.2* ,.01
NS 5 13.3* 9.1* ,.01
,.01 2.5 26.7* 15.2* ,.001
P value Reporting yes, n (%) P value
12 (38.7)* ,.001 7 (17.5) 4 (26.7) 14 (42.4)* ,.001
8 (25.8)* ,.01 4 (10.0) 2 (13.3) 9 (27.3)* ,.01
0 (0) NS 2 (5.0) 1 (6.7) 2 (6.1) NS
3 (9.7) NS 0 (0) 0 (0) 4 (12.1)* ,.05
2 (6.5)* ,.05 1 (2.5) 1 (6.7) 2 (6.1) NS
1 (3.2) ,.01 2 (5.0) 1 (6.7) 2 (6.1) ,.01
t; NS, not significant; IADLs, instrumental activities of daily living.
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a relatively young cohort. There are several important
contributions from this study, including the reporting of
incidence rates of MCD in this age group, evaluation of
stability of diagnoses, and documentation of the impact of
MCD on everyday life.
After 8 years of follow-up, approximately 10% of this
sample age 68 to 72 years at wave 3 had MCD after correct-
ing statistically for false negatives and attrition. As expected
from the younger age sample, incidences of MCI and any
MCD were less than one third of the 63.6/1000 recently re-
ported in the Mayo Clinic Study of Aging for a sample age
70 to 89 years at baseline [1]. The incidence rates were also
at the lower end of the range reported in a recent review [37].
These rates are likely to underestimate the true level of MCD
in the population because the sample had relatively few par-
ticipants with a low level of education, which is the strongest
risk factor for MCI [38]. Moreover, there is greater attrition
among participants with cognitive disorders in longitudinal
studies [39], particularly at older ages [40]. Previous studies
have also found that the prevalence of MCI is determined by
the criteria used [41]. As noted by Petersen and colleagues
[42] and Ritchie [43], epidemiologic study samples include
far greater heterogeneity than clinical samples.
Approximately half of all diagnoses in this age group are
unstable. Only five participants with MCD converted to de-
mentia during our 8 years of follow-up, which is close to the
low rate of progression reported in another study that com-
menced at age 60 [44], and was lower than the progression
rates reported for studies with older age ranges [42]. These
results emphasize the importance of considering the age of
the sample when evaluating rates of progression from MCI
to dementia. Although participants received clinical diagno-
ses and reported difficulties in IADLs, MMSE scores were
not low.
The clinical indicators of stability of diagnosis included
higher levels of depression at baseline and lower MMSE
scores. Unlike previous studies, we did not find that the
APOE genotype was associated with MCI [45], and this
may be a result of the heterogeneity in our epidemiologic
sample. However, 50% of the eight dementia cases had at
least one e4 allele, and further follow-up of the cohort will
determine whether higher rates of conversion are found
among APOE-positive MCD-classified participants.
The characteristics of participants at risk of cognitive im-
pairment were consistent with the literature. Our finding of
baseline depression being higher in participants converting
to MCI is consistent with previous research showing that
late-life depression is associated with increased risk of AD
and dementia [46,47]. Our finding of a higher Framingham
risk score at baseline in the MCD group is consistent with
previous research from the Whitehall study [32] linking
this measure with poorer cognitive function and cognitive
decline in men. Similar to the Mayo study [1], we found
that low education and males were at increased risk. What
is particularly interesting in relation to the protective effectof education is that the mean difference in years of education
between those with MCI/MCD and cognitively normal sub-
jects is that it only differed by 2 years. Moreover, this differ-
ence occurred among groups with relatively high levels of
education (approximately 12 years vs approximately 14
years).
This study also documents the impact of MCDs on ev-
eryday function in adults in their 60s. Consistent with
other studies in older samples, impairment in some but
not all IADLs was found [48], indicating that these adults
living in the community already experience disability asso-
ciated with their cognitive disorder. The greater level of
impairment in IADLs in the groups with stable diagnoses
is consistent with previous research indicating that impair-
ment in IADL predicts faster progression to AD and
greater brain atrophy [49]. Compared with the normally
aging participants in our study, we found that the MCD
group reported higher rates of memory problems interfer-
ing with their everyday lives, lower rates of employment,
and higher rates of difficulties with IADLs [49]. Criteria
for MCI include minimal impairment on complex instru-
mental functions, and this was established during diagnosis
using the Informant Questionnaire for Cognitive Decline in
the Elderly and an informant interview. Our findings indi-
cate that those with stable MCD are aware of and more
likely to endorse difficulties with complex IADLs relative
to the healthy population. The items used to assess IADLs
in this study were drawn from the U.S. Health and Retire-
ment Study [25] and may have been more sensitive to im-
pairment in higher level IADLs than items designed for
clinical use when impairment is greater. Hence, even in
this relatively highly educated cohort, a small proportion
experience disability in their 60s as a result of cognitive
impairment.
Limitations included sample attrition and a primarily
white and highly educated population. Strengths of this
study include the population-based sample of relatively
young age, a narrow cohort design that allows for aging ef-
fects to be studied distinct from cohort effects, the availabil-
ity of 8 years of follow-up data, and the thorough clinical
assessment and consensus diagnosis by clinicians using pub-
lished criteria. We also used statistical models with boot-
strapping to minimize error in our prevalence estimates,
adjusted for false negatives, and evaluated statistically the
impact of sample attrition on incidence.
The detection of MCI in this younger age group suggests
that a proportion of those diagnosed in the older cohort stud-
ies may have been impaired for many years, and hence the
duration of the clinically detectable MCI phase may be lon-
ger than previously considered. This is consistent with the
model of biomarkers of AD showing disease progression de-
cades prior to diagnosis [50]. We conclude that MCDs in in-
dividuals in their 60s occur in at least 10% of the population
and are likely to be heterogeneous in terms of their etiology
and long-term prognosis, but may cause a significant impact
on everyday life.
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1. Systematic review: We searched reports from large
cohort studies and systematic reviews to identify
studies reporting on the epidemiology of mild cogni-
tive disorders in early old age. No study with a large
cohort aged early 60s was identified. Nearly all re-
search on mild cognitive impairment has been on
adults in their 70s and 80s.
2. Interpretation: In their late 60s, about 10% of our
cohort had progressed to a mild cognitive disor-
der, with 8% meeting diagnostic criteria for
mild cognitive impairment. Cognitive impairment
was associated with difficulties in instrumental
activities of daily living. Stable diagnoses (about
45%) were associated with lower Mini-Mental
State Examination scores, history of neurologi-
cal disorder, higher cardiovascular risk, and de-
pression at baseline.
3. Future directions: Correlation of cognitive impair-
ment in late middle age and early old age with
biomarkers of Alzheimer’s disease and other demen-
tias will assist in characterizing and differentiating
more completely the course and causes of dementia,
optimizing targeting of interventions.
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